BOSTON --(BUSINESS WIRE)--Nov. 26, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today

BOSTON, Mass. --(BUSINESS WIRE)--Nov. 20, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain,

BOSTON --(BUSINESS WIRE)--Nov. 18, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today

KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo Improvement in Total PANSS Score at Five Weeks was 11.6 Points Compared to Placebo (p

BOSTON --(BUSINESS WIRE)--Nov. 17, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today

Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in Alzheimer’s disease and pain on track to commence by the end of 2019 Cash, cash

BOSTON --(BUSINESS WIRE)--Aug. 28, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled

Completed multiple financings in 2019, including initial public offering, raising $184.7 million to fund clinical development of novel CNS pipeline Results from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track to report data in

BOSTON --(BUSINESS WIRE)--Aug. 6, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that Andrew Miller , Ph.D., founder and chief operating

BOSTON --(BUSINESS WIRE)--Jul. 2, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the closing of its initial public offering of 6,414,842